Impact of smoking on diagnosis and survival of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) patients, Pulmonology, 2026

Exposure to cigarette smoke is a well-recognised risk factor for endothelial dysfunction, which causes changes in pulmonary vascular architecture and can lead to pulmonary hypertension — and notably, these changes occur at an early stage of smoking-related lung disease, long before airway obstruction develops. Despite this, the specific impact of smoking on pulmonary arterial hypertension […]

Impact of smoking on diagnosis and survival of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) patients, Pulmonology, 2026 Read Post »

Study links allergy molecule to worsening heart function in pulmonary arterial hypertension, Pulmonary Hypertension News, March 11, 2026

A study published in Pulmonary Circulation and reported in the March 11 issue of Pulmonary Hypertension News, has found that higher blood levels of immunoglobulin E (IgE) — an immune molecule normally associated with allergies — are linked to worse right heart function in pulmonary arterial hypertension patients. Those with elevated IgE levels showed more

Study links allergy molecule to worsening heart function in pulmonary arterial hypertension, Pulmonary Hypertension News, March 11, 2026 Read Post »

Martine Rothblatt, founder and CEO of United Therapeutics, included in Forbes’ America’s Greatest Innovators list

Martine Aliana Rothblatt (born 1954) is an American lawyer, author, and entrepreneur. She founded United Therapeutics in 1996, to make medicines for her daughter who suffered from pulmonary arterial hypertension, and is now developing genetically modified pig organs for human transplant. On the latter topic she has written a book titled “Your life or mine

Martine Rothblatt, founder and CEO of United Therapeutics, included in Forbes’ America’s Greatest Innovators list Read Post »

Sotatercept in pulmonary arterial hypertension: A step-by-step approach for considering the new kid on the block, CHEST, March 4, 2026

Since sotatercept received Food and Drug Administration (FDA) approval for pulmonary arterial hypertension in March 2024, knowing when and how to use it has become an essential part of managing this serious condition — so say the authors of a recently published article in CHEST, who offer a practical guide for clinicians navigating this new

Sotatercept in pulmonary arterial hypertension: A step-by-step approach for considering the new kid on the block, CHEST, March 4, 2026 Read Post »

A Proof of Concept for the Use of Lung Ultrasound in the Diagnostic Approach of Pulmonary Hypertension, CHEST, March 2026

The authors of a study recently published on CHEST retrospectively analyzed data from adult patients enrolled in the French Pulmotension registry (Commission Nationale de l’Informatique et des Libertés No. 842063) from the Limoges Competence Center between May 1, 2020, and May 1, 2021. Inclusion criteria were the following: (1) confirmed pulmonary hypertension (PH) diagnosed by

A Proof of Concept for the Use of Lung Ultrasound in the Diagnostic Approach of Pulmonary Hypertension, CHEST, March 2026 Read Post »

A Comprehensive literature review on the pathophysiology, mechanism, diagnosis, and management of pulmonary arterial hypertension, US Cardiology Review, January 28, 2026

This review covers the full clinical picture of pulmonary arterial hypertension (PAH) — from its pathophysiology and diagnosis through to current and emerging treatments. Understanding the Disease Pulmonary arterial hypertension is driven by progressive structural remodelling of the pulmonary arteries, creating a vicious cycle of vasoconstriction, inflammation, and uncontrolled cell growth that ultimately leads to

A Comprehensive literature review on the pathophysiology, mechanism, diagnosis, and management of pulmonary arterial hypertension, US Cardiology Review, January 28, 2026 Read Post »

Treatment paradigm shifts in pulmonary arterial hypertension: evidence from a phase 3 study in Asia on sotatercept, JACC, March 3, 2026

A Japanese study has confirmed that sotatercept works just as well in Asian patients, even though pulmonary arterial hypertension presents somewhat differently in the Asian population: patients tend to have longer disease duration, more severe baseline profiles, and are more frequently on intensive triple therapy including parenteral prostacyclin. This was a regional Phase 3, open-label

Treatment paradigm shifts in pulmonary arterial hypertension: evidence from a phase 3 study in Asia on sotatercept, JACC, March 3, 2026 Read Post »

European Society of Cardiology (ESC) announces launch of the plain language version of the guidelines on cardio-vascular disease in pregnancy on March 8, 2026, International Women’s Day

This International Women’s Day, the European Society of Cardiology (ESC) proudly announced the launch of the patient version of the 2025 guidelines on the management of cardiovascular disease (CVD) in pregnancy. Pregnancy is a life-changing experience — but for women living with cardiovascular disease, it comes with an additional layer of complexity, uncertainty, and anxiety.

European Society of Cardiology (ESC) announces launch of the plain language version of the guidelines on cardio-vascular disease in pregnancy on March 8, 2026, International Women’s Day Read Post »

Methamphetamine-Associated pulmonary arterial hypertension: a growing and distinct patient population, Journal of Heart and Lung Transplant, March 5, 2026

A large US claims-based study has shed light on a worrying trend: pulmonary arterial hypertension linked to methamphetamine use (Meth-APAH) is rising fast — up 93% between 2018 and 2022, a rate disproportionate to the general rise in methamphetamine use itself. Compared to other pulmonary arterial hypertension patients, those with Meth-APAH tend to be younger,

Methamphetamine-Associated pulmonary arterial hypertension: a growing and distinct patient population, Journal of Heart and Lung Transplant, March 5, 2026 Read Post »

Video recording & full transcript (translatable in 40 languages) now available for the Pulmonary Hypertension Expert Patient Academy (PHEPA) joint Alliance for Pulmonary Hypertension and PHA Europe project

LINK TO VIDEO TRANSCRIPT Can be translated in 40 languges, check orange button on bottom of page Gergely Meszaros: Good evening and good afternoon to everyone. Welcome to this webinar introducing the Pulmonary Hypertension Expert Patient Academy (PHEPA). I’m delighted to present this new initiative. When ERN-LUNG, the European Reference Network for Rare Respiratory Diseases,

Video recording & full transcript (translatable in 40 languages) now available for the Pulmonary Hypertension Expert Patient Academy (PHEPA) joint Alliance for Pulmonary Hypertension and PHA Europe project Read Post »

United Therapeutics announces results for its Phase 3 ADVANCE OUTCOMES study on ralenipag for pulmonary arterial hypertension, March 2, 2026

United Therapeutics has announced promising results from its pivotal Phase 3 ADVANCE OUTCOMES study of ralinepag, a new oral treatment for pulmonary arterial hypertension (PAH). Ralinepag is a highly selective prostacyclin (IP) receptor agonist that works through multiple pathways — vasodilatory, anti-proliferative, and anti-inflammatory. It is taken once daily orally, yet achieves sustained receptor activity

United Therapeutics announces results for its Phase 3 ADVANCE OUTCOMES study on ralenipag for pulmonary arterial hypertension, March 2, 2026 Read Post »

2025 expert consensus on the use of parenteral prostanoids in incident and prevalent PAH patients: The Italian perspective, Vascular Pharmacology, February 28, 2026

A consensus document featuring 10 statements, the main focus of which was the use of parenteral prostanoids, was developed by eight experts in pulmonary arterial hypertension during in-person and web-based meetings. Forty-six Italian physicians were invited online to rate each statement, indicating their agreement, neutrality or disagreement. These consensus statements are intended to support physicians

2025 expert consensus on the use of parenteral prostanoids in incident and prevalent PAH patients: The Italian perspective, Vascular Pharmacology, February 28, 2026 Read Post »

Nippon Shinyaku reports progress on trials on NS-863 targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)

Nippon Shinyaku recently reported progress on two Phase 2 trials of its oral candidate NS-863, targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), both serious cardiopulmonary conditions with high unmet need. By advancing NS-863 across two related indications, the company is signaling a deeper push into rare cardiopulmonary therapeutics,

Nippon Shinyaku reports progress on trials on NS-863 targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) Read Post »

Comparing survival and comorbidities between two sub-groups of pulmonary arterial hypertension from the Spanish REHAP Registry, Rheumatology (Oxford), February 27, 2026

A retrospective study based on data from the Spanish pulmonary arterial hypertension Registry (REHAP) set out to compare the demographic and clinical profiles, comorbidity burden, and survival rates of patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) against those with idiopathic pulmonary arterial hypertension (IPAH). The study, covering the period 2014–2023, included 757 patients

Comparing survival and comorbidities between two sub-groups of pulmonary arterial hypertension from the Spanish REHAP Registry, Rheumatology (Oxford), February 27, 2026 Read Post »

Tenax Therapeutics extends long-term study of oral levosimendan (TNX-103) in pulmonary hypertension with preserved ejection fraction (HFpEF) patients, February 2026

Tenax Therapeutics is conducting a long-term open-label extension study of TNX-103, an oral formulation of levosimendan, in patients with pulmonary hypertension associated with heart failure and preserved Ejection Fraction (HFpEF), Group 2 of the World Health Organisation classification. In its intravenous form TNX-103 is a drug authorized for use in 60 countries for acute decompensated

Tenax Therapeutics extends long-term study of oral levosimendan (TNX-103) in pulmonary hypertension with preserved ejection fraction (HFpEF) patients, February 2026 Read Post »

GSK set to buy 35Pharma, currently investigating drug for pulmonary arterial hypertension and pulmonary hypertension due to heart failure with preserved ejection fraction, February 25, 2026

GSK, a UK pharmaceutical multinational, has agreed to acquire 35Pharma, a private Canadian clinical-stage biopharmaceutical company, for $950m in cash.   The transaction will provide GSK with full ownership of 35Pharma and its lead investigational medicine, HS235, an activin receptor signalling inhibitor currently positioned for studies in pulmonary arterial hypertension (PAH) and pulmonary hypertension due to

GSK set to buy 35Pharma, currently investigating drug for pulmonary arterial hypertension and pulmonary hypertension due to heart failure with preserved ejection fraction, February 25, 2026 Read Post »

New edition of the German pulmonary hypertension association ph e.v. magasine RUNDBRIEF, February 2026

Here is the AI translation of the index. Patient Community & Events Regional Association Updates (Landesverbände) Reports from local pulmonay hypertension chapters across Germany, covering Baden-Württemberg, Bavaria, Berlin/Brandenburg/Mecklenburg-Vorpommern, Hamburg/Schleswig-Holstein, Hesse, North Rhine-Westphalia, Saxony, and Saarland/Rhineland-Palatinate (pp. 16–33), plus a directory of regional leaders (p. 33). Medical & Scientific Topics Practical Patient Information Policy & Advocacy

New edition of the German pulmonary hypertension association ph e.v. magasine RUNDBRIEF, February 2026 Read Post »

Defying Limits: Eight transplant recipients accompanied by medical team from Vienna, climb Aconcagua (6,961 meters), in Argentina – the highest peak in the Americas!

AI translation of article on MedUni, Vienna, Austria news, available in German at this link Vienna, February 25, 2026 – In January 2026, eight lung transplant recipients and their companions from five nations, together with a medical team from MedUni Vienna, climbed Aconcagua (6,961 meters) in Argentina – the highest peak in the Americas. During

Defying Limits: Eight transplant recipients accompanied by medical team from Vienna, climb Aconcagua (6,961 meters), in Argentina – the highest peak in the Americas! Read Post »

Results of the PROSERA study for seralutinib in pulmonary arterial hypertension released by Gossamer Bio on February 23, 2026

The PROSERA study for seralutinib in pulmonary arterial hypertension findings were released yesterday and report that it did not meet its primary endpoint in the full population. It appears that unexpected placebo results in some geographical areas may have been responsible for this happening. While this is disappointing news for the patient community the program

Results of the PROSERA study for seralutinib in pulmonary arterial hypertension released by Gossamer Bio on February 23, 2026 Read Post »

The UK’s pulmonary hypertension association free resource of the month is a four week program to address depression

Developed by psychologists, and supported by the UK’s pulmonary hyeprtension association, PHA UK, this four-week programme consists of a series of workbooks based on Cognitive Behavioural Therapy (CBT), to help patients change their thinking habits and behaviours. Find our more at this link on the PHA UK website

The UK’s pulmonary hypertension association free resource of the month is a four week program to address depression Read Post »

TRANSLATE »
Scroll to Top